Tumour Lysis Syndrome in a Patient with Metastatic Gastrointestinal Stromal Tumour Treated with Imatinib
Author Information
Author(s): Elizabeth M. Pinder, Gurprit S. S. Atwal, Abraham A. Ayantunde, Sarah Khan, Mike Sokal, Tom McCulloch, Simon L. Parsons
Primary Institution: Nottingham City Hospital
Hypothesis
This case report aims to describe the occurrence of tumour lysis syndrome (TLS) in a patient with metastatic gastrointestinal stromal tumour treated with imatinib.
Conclusion
The patient experienced tumour lysis syndrome as a direct consequence of imatinib treatment for gastrointestinal stromal tumour.
Supporting Evidence
- The patient developed classic features of tumour lysis syndrome after starting imatinib.
- Post-mortem examination revealed significant tumour cell kill consistent with the effects of imatinib.
- The patient had multiple risk factors for TLS, including compromised renal function and bulky tumour.
Takeaway
This study talks about a man who got very sick after taking a medicine for his stomach cancer, which caused his body to react badly and led to serious health problems.
Methodology
Case report detailing the clinical course and post-mortem findings of a patient treated with imatinib.
Limitations
The case report is based on a single patient, limiting generalizability.
Participant Demographics
An 81-year-old man with a history of gastrointestinal stromal tumour and other comorbidities.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website